Teclistamab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Teclistamab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
64
Registered trials
204
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Teclistamab can convert its Bispecific T-cell Engager (BiTE) profile and BCMA x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Teclistamab (query alias: teclistamab) |
|---|---|
| Modality / target | Bispecific T-cell Engager (BiTE); BCMA x CD3; BCMA modulators, CD3 stimulants |
| Highest global status | Approved |
| Originator | Janssen Research & Development LLC |
| Active developers | Janssen Research & Development LLC, Clinigen Clinical Supplies Management, Johnson & Johnson (China) Investment Ltd. |
The MCP disease footprint includes Refractory Multiple Myeloma, Relapse multiple myeloma, Multiple Myeloma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07649525 | Phase 3 | Not yet recruiting | 1226 | iFIT1: Progression-free survival (PFS) |
| NCT07671287 | Phase 3 | Not yet recruiting | 399 | To determine the efficacy (MRD negativity at a level of 10-6) of Tec-DRd compared to DVRd after induction/consolidation therapy and HD melphalan and ASCT, before start of maintenance therapy in participants with TE NDMM |
| NCT07657312 | Phase 2 | Recruiting | 35 | Incidence of all-grade cytokine release syndrome (CRS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
BCMA TARGETED T-CELL ENGAGER TECLISTAMAB AS RESCUE THERAPY FOR SEVERE REFRACTORY AUTOIMMUNE DISEASES
Not Applicable; n=16; evaluation: Positive. Reported fields: CRS = 13.0 Pts
TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL
Phase 2; n=59; evaluation: Positive. Reported fields: AE(Grade ≥3) = Grade ≥3 AEs included neutropenia (Tec 16/45, 36% [gr4, n=8]; Rd 11/14, 79% [gr4, n=4]), thrombocytopenia (Tec 2/45, 4% [gr4, n=1]; Rd 2/14, 14%), infections (Tec 9/45, 20%; Rd 3/14, 21.4%) and ALT/AST elevation (Tec 5/45, 11%; Rd 1/14, 7%). Grade ≥3 lymphopenia occurred only in the Tec arm (4/45, 9% [gr4, n=1]) as well as one gastrointestinal AE (2.2%). ; AE(Grade ≥3) = Grade ≥3 AEs included neutropenia (Tec 16/45, 36% [gr4, n=8]; Rd 11/14, 79% [gr4, n=4]), thrombocytopenia (Tec 2/45, 4% [gr4, n=1]; Rd 2/14, 14%), infections (Tec 9/45, 20%; Rd 3/14, 21.4%) and ALT/AST elevation (Tec 5/45, 11%; Rd 1/14, 7%). Grade ≥3 lymphopenia occurred only in the Tec arm (4/45, 9% [gr4, n=1]) as well as one gastrointestinal AE (2.2%).
Updated two-year overall survival and toxicity outcomes of BCMA CAR-T therapy compared with teclistamab in multiple myeloma.
Not Applicable; n=227; evaluation: Positive. Reported fields: CRS: HR = 1.48(95.0% CI, 1.12 - 1.96), P-Value = 0.003; CRS: HR = 1.48(95.0% CI, 1.12 - 1.96), P-Value = 0.003
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Teclistamab addresses Refractory Multiple Myeloma, Relapse multiple myeloma, Multiple Myeloma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2020-09-14 | SpringWorks and Janssen will assess the efficacy of nirogacestat combined with teclistamab for the treatment of multiple myeloma. | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with proteasome inhibitors”. The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with an immunomodulator”. The milestone feed surfaced a patent-application signal described as “Methods of treating multiple myeloma with BCMA inhibitors in combination with CD38 inhibitors”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Cytokine-release syndrome, neurotoxicity, and infection
- Durability after deep B-cell or plasma-cell depletion
- Dose-step-up logistics, manufacturing, and outpatient feasibility
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
